<div id="readability-page-1"><p>Ameriprise Financial Inc. purchased a new stake in shares of  Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  purchased 22,584 shares of the company's stock, valued at approximately $603,000.</p><div><p><span></span><span>Get <strong>Edgewise Therapeutics</strong> alerts:</span></p></div><ul><li>MarketBeat Week in Review – 9/23 - 9/27</li></ul><p>Other hedge funds also recently bought and sold shares of the company. Diadema Partners LP bought a new stake in  Edgewise Therapeutics during the fourth quarter valued at about $36,000.  Aquatic Capital Management LLC bought a new stake in  Edgewise Therapeutics during the fourth quarter valued at about $77,000.  Tower Research Capital LLC TRC boosted its holdings in  Edgewise Therapeutics by 1,097.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,676 shares of the company's stock valued at $98,000 after acquiring an additional 3,369 shares during the period.  Quantbot Technologies LP bought a new stake in  Edgewise Therapeutics during the fourth quarter valued at about $103,000.  Finally, KLP Kapitalforvaltning AS bought a new stake in  Edgewise Therapeutics during the fourth quarter valued at about $182,000. </p><h2>Edgewise Therapeutics Stock Up 1.0%</h2><p>NASDAQ:EWTX opened at $14.84 on Wednesday. Edgewise Therapeutics, Inc. has a 12-month low of $10.60 and a 12-month high of $38.12. The firm has a market capitalization of $1.56 billion, a PE ratio of -9.89 and a beta of 0.36. The firm has a 50-day moving average price of $14.57 and a 200 day moving average price of $23.21. </p><ul><li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li></ul><p>Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.02.  On average, research analysts expect that  Edgewise Therapeutics, Inc. will post -1.45 EPS for the current year. </p><h2>Insider Activity at Edgewise Therapeutics</h2><p>In other Edgewise Therapeutics news, insider Alan J. Russell sold 1,551 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $16.45, for a total value of $25,513.95. Following the transaction, the insider now directly owns 18,521 shares of the company's stock, valued at approximately $304,670.45. This trade represents a 7.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc purchased 496,771 shares of Edgewise Therapeutics stock in a transaction dated Thursday, April 3rd. The shares were purchased at an average cost of $20.13 per share, for a total transaction of $10,000,000.23. Following the completion of the transaction, the director now owns 14,809,075 shares of the company's stock, valued at approximately $298,106,679.75. This represents a 3.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 14,258 shares of company stock valued at $234,544 over the last quarter. Corporate insiders own  23.20% of the company's stock. </p><h2>Analyst Ratings Changes</h2><ul><li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li></ul><p>EWTX has been the subject of several research reports. Royal Bank of Canada reduced their target price on shares of Edgewise Therapeutics from $56.00 to $52.00 and set an &#34;outperform&#34; rating for the company in a research note on Thursday, April 3rd. Guggenheim initiated coverage on shares of Edgewise Therapeutics in a research note on Wednesday, April 30th. They issued a &#34;buy&#34; rating and a $41.00 target price for the company. Scotiabank cut shares of Edgewise Therapeutics from a &#34;sector outperform&#34; rating to a &#34;sector perform&#34; rating and reduced their target price for the company from $50.00 to $14.00 in a research note on Wednesday, April 2nd. Piper Sandler  reiterated an &#34;overweight&#34; rating and issued a $51.00 target price on shares of Edgewise Therapeutics in a research note on Wednesday, April 2nd. Finally, Wedbush  reiterated an &#34;outperform&#34; rating and issued a $43.00 target price on shares of Edgewise Therapeutics in a research note on Monday, April 21st. Two analysts have rated the stock with a hold rating and seven have assigned  a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $40.22.</p><p><b>Get Our Latest Stock Analysis on Edgewise Therapeutics</b></p><h2>Edgewise Therapeutics Company Profile</h2> (Free Report)<p>Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.</p><h2>See Also</h2><ul><li>Five stocks we like better than Edgewise Therapeutics</li><li>Low PE Growth Stocks: Unlocking Investment Opportunities</li><li>Among the Market’s Most Shorted: 2 Firms With +40% Short Interest</li><li>What Is WallStreetBets and What Stocks Are They Targeting?</li><li>Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next</li><li>How to Invest in Biotech Stocks</li><li>Rocket Lab Expands Into Payloads: Should You Be Paying Attention?</li></ul><p><strong>Want to see what other hedge funds are holding EWTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Edgewise Therapeutics Right Now?</h2><p>Before you consider Edgewise Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.</p><p>While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EWTX

<p>Ameriprise Financial Inc. acquired 22,584 shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) valued at approximately $603,000 in the fourth quarter, as reported in its recent SEC filing. Other institutional investors also increased their stakes in the company. Edgewise Therapeutics' stock opened at $14.84, with a market cap of $1.56 billion. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average target price of $40.22.</p>

22,584 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by Ameriprise Financial Inc.